Neoadjuvant therapy for potentially resectable pancreatic cancer: An emerging paradigm?

Current Oncology Reports

Volumn 15, Issue 2, 2013, Pages 162-169

  Brunner, Thomas B ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Borderline resectable; Neoadjuvant chemoradiotherapy; Pancreatic cancer; Potentially resectable

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEMCITABINE; MITOMYCIN; STREPTOZOCIN;

ADJUVANT CHEMORADIOTHERAPY; ARTICLE; BORDERLINE RESECTABLE PANCREAS CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED RADIOTHERAPY; CONTINUOUS INFUSION; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; HYPERBILIRUBINEMIA; INOPERABLE CANCER; INTRAOPERATIVE RADIOTHERAPY; LEUKOPENIA; NAUSEA AND VOMITING; PANCREAS CANCER; PANCREAS RESECTION; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; QUALITY OF LIFE; SIDE EFFECT; STENT THROMBOSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84879602757     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0291-3     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Crane CH, Varadhachary GR, Yordy JS, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011;29:3037-43.
3. Brunner TB, Geiger M, Grabenbauer GG, et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol. 2008;26:2699-706.
4. Fokas E, Prevo R, Pollard JR, et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012;3:e441.
5. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496-502.
6. Pingpank JF, Hoffman JP, Ross EA, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001;5:121-30.
7. Tinkl D, Grabenbauer GG, Golcher H, et al. Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation. Strahlenther Onkol. 2009;185:557-66.
8. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997;15:928-37.
9. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-79.
10. Wayne JD, Wolff RA, Pisters PW, et al. Multimodality management of localized pancreatic cancer. Cancer J. 2001;7 Suppl 1:S35-46.
11. Rumstadt B, Schwab M, Schuster K, et al. The role of laparoscopy in the preoperative staging of pancreatic carcinoma. J Gastrointest Surg. 1997;1:245-50.
12. Brunner TB, Fokas E, Eccles C, et al. A comparison of four target volume definitions for pancreatic cancer: two concepts including the lymphatics (RTOG & ARO) and two concepts only treating the primary tumour (Michigan & UK-SCALOP). Poster 2274 presented at the ASTRO annual meeting 2012, Boston.
13. Tamm EP, Loyer EM, Faria S, et al. Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdom Imaging. 2006;31:568-74.
14. Cheng TY, Sheth K, White RR, et al. Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. Ann Surg Oncol. 2006;13:66-74.
15. •• Brunner TB, Golcher H, Witzigmann H, et al. Results of a multicenter randomized phase II trial of resection ± neoadjuvant chemoradiation therapy in pancreatic cancer. Int J Radiat Oncol Biol Phys. 2012;84:S90-1. This is the first multicentre randomised controlled trial comparing primary resection versus neoadjuvant chemoradiotherapy followed by resection in pancreatic cancer. Median overall survival of patients with resected tumours was 25 versus 18 months, preoperative therapy was safe and the clear resection rate was higher after pretreatment.
16. Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR Am J Roentgenol. 1997;168:1439-43.
17. Brunner TB, Merkel S, Grabenbauer GG, et al. Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based upon histopathologic analysis. Int J Radiat Oncol Biol Phys. 2005;62:1021-9.
18. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-13.
19. Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25:326-31.
20. •• Gillen S, Schuster T, Meyer Zum Buschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267. This is an important meta-analysis on neoadjuvant chemoradiotherapy for both resectable and non-resectable tumours.
21. Boeck S, Bruns CJ, Sargent M, et al. Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society. Oncology. 2009;77:40-8.
22. Assifi MM, Lu X, Eibl G, et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011;150:466-73.
23. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806-13.
24. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
25. Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1998;16:317-23.
26. Staley CA, Lee JE, Cleary KR, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg. 1996;171:118-24.
27. Pisters PW, Abbruzzese JL, Janjan NA, et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol. 1998;16:3843-50.
28. Moutardier V, Magnin V, Turrini O, et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2004;60:437-43.
29. Le Scodan R, Mornex F, Girard N, et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol. 2009;20:1387-96.
30. Zhu CP, Shi J, Chen YX, et al. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol. 2011;99:108-13.
31. • Papalezova KT, Tyler DS, Blazer 3rd DG, et al. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol. 2012;106:111-8. This is a large retrospective comparison of 144 patients with resectable PDAC who had preoperative chemoradiotherapy with 92 patients who had immediate surgery. Median overall survival of resected patients was 26 versus 17 months (p = 0.04).
32. •• Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727-33. This article provides the expert consensus definition of resectable, borderline resectable and non-resectable pancreatic tumours which should be employed to classify patients with localised pancreatic tumours.
33. Tempero M, Arnoletti J, Behrman S, et al. NCCN clinical practice guidelines in oncology. Pancreatic adenocarcinoma. 2010, pp 1-52
34. Snady H, Bruckner H, Cooperman A, et al. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer. 2000;89:314-27.
35. Golcher H, Brunner T, Grabenbauer G, et al. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Eur J Surg Oncol. 2008;34:756-64.
36. Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118:5749-56.
37. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833-46. discussion 846-8.
38. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035-46.
39. Chatterjee D, Katz MH, Rashid A, et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012;118:3182-90.
40. Bang S, Chung HW, Park SW, et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol. 2006;40:923-9.
41. Choi M, Heilbrun LK, Venkatramanamoorthy R, et al. Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer. Am J Clin Oncol. 2010;33:257-61.
42. Heinrich S, Schafer M, Weber A, et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg. 2008;248:1014-22.
43. Topkan E, Parlak C, Kotek A, et al. Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy. BMC Gastroenterol. 2011;11:123.
44. Tzeng CW, Fleming JB, Lee JE, et al. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012;19:2045-53.